Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study
- PMID: 19932513
- DOI: 10.1016/j.jneuroim.2009.10.013
Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study
Abstract
Interferon-beta (IFN-beta) is an immunomodulatory drug of choice to control relapsing-remitting multiple sclerosis (RR-MS), although its function is still unclear. A reduced suppressive function of CD4(+)CD25(+) regulatory T cells (T(reg)) has been shown in RR-MS patients. In this study, to understand the effect of IFN-ss on CD4(+)CD25(+) regulatory T cells, we analyzed the frequency and function of these cells and Foxp3 gene expression before and after treatment. We evaluated the frequency and function of CD4(+)CD25(+)Foxp3(+) regulatory T cells by flow cytometry and co-culture inhibition test respectively and gene expression of Foxp3 by real-time PCR in a longitudinal follow-up study in 18 relapsing-remitting MS patients. Our data revealed that IFN-beta significantly improved frequency and suppressive function of T(reg) cells (P<0.05) without any significant effect on gene expression of Foxp3 after 6 months. The results of the present study indicate that IFN-beta therapy in some of patients with RR-MS may restore function of regulatory T cells and control the unchecked immune cascade activity. Larger longitudinal studies on more MS patients are required to confirm our findings.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.J Neurosci Res. 2006 Jun;83(8):1432-46. doi: 10.1002/jnr.20852. J Neurosci Res. 2006. PMID: 16583400
-
Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.Arch Neurol. 2008 Nov;65(11):1434-9. doi: 10.1001/archneur.65.11.1434. Arch Neurol. 2008. PMID: 19001161
-
Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.Immunology. 2008 Jan;123(1):79-89. doi: 10.1111/j.1365-2567.2007.02690.x. Epub 2007 Sep 25. Immunology. 2008. PMID: 17897326 Free PMC article.
-
Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.Clin Neurol Neurosurg. 2010 Sep;112(7):641-5. doi: 10.1016/j.clineuro.2010.04.020. Epub 2010 Jun 1. Clin Neurol Neurosurg. 2010. PMID: 20570038 Review.
-
Disturbed regulatory T cell homeostasis in multiple sclerosis.Trends Mol Med. 2010 Feb;16(2):58-68. doi: 10.1016/j.molmed.2009.12.003. Trends Mol Med. 2010. PMID: 20159585 Review.
Cited by
-
Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis.Immunol Res. 2018 Aug;66(4):513-520. doi: 10.1007/s12026-018-9008-5. Immunol Res. 2018. PMID: 29882035
-
One, No One, and One Hundred Thousand: T Regulatory Cells' Multiple Identities in Neuroimmunity.Front Immunol. 2019 Dec 20;10:2947. doi: 10.3389/fimmu.2019.02947. eCollection 2019. Front Immunol. 2019. PMID: 31956323 Free PMC article. Review.
-
Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets.Pharmaceutics. 2023 Feb 22;15(3):728. doi: 10.3390/pharmaceutics15030728. Pharmaceutics. 2023. PMID: 36986586 Free PMC article. Review.
-
Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.Int J Mol Sci. 2016 Aug 25;17(9):1398. doi: 10.3390/ijms17091398. Int J Mol Sci. 2016. PMID: 27571060 Free PMC article.
-
IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type I IFN-dependent inflammatory disease.J Immunol. 2014 Sep 15;193(6):2733-42. doi: 10.4049/jimmunol.1401039. Epub 2014 Aug 4. J Immunol. 2014. PMID: 25092894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials